• ROVI forecasts that its 2024 operating revenue will be multiplied by between 1.5 and 1.8 in six years, driven primarily by an increase in its contract manufacturing business sales.
• The company will reinforce its current position as one of the major global leaders in the fill and finish of injectables after expanding its installed capacity.
• ROVI expects the specialty pharmaceutical division to grow annually by a low-single-digit percentage in the period from 2024 to 2030, with Okedi® as the primary growth driver.
• The company plans to commence the next phases of the clinical development of Letrozole SIE and three-monthly risperidone.

Madrid, 25 March 2025.- At its Capital Markets day today, Laboratorios Farmacéuticos Rovi, S.A. (BME: ROVI), a pan-European pharmaceutical company specialising and engaged in the research and development, contract manufacturing and marketing of small molecules and specialty biologics, announced important information on its financial performance, long-term strategy and growth prospects for the next six years. ROVI is committed to investing in its business in order to increase its production capacities and thus address the current imbalance between supply and demand, reinforce the company’s internationalisation through Risperidone ISM® – its first proprietary innovative product based on ISM® technology –, and strengthen its product portfolio with new proprietary drugs based on ISM® technology, such as Letrozole SIE and three-monthly risperidone.